Related references
Note: Only part of the references are listed.IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky et al.
CLINICAL CANCER RESEARCH (2018)
Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
Cristina Gutierrez-Vazquez et al.
IMMUNITY (2018)
A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2
Avinoam Nevler et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
Jae Eun Cheong et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients
Weili Wang et al.
CANCER RESEARCH (2018)
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'
George C. Prendergast et al.
TRENDS IN CANCER (2018)
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology
Eddy W. Yue et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Discovery of IDO1 Inhibitors: From Bench to Bedside
George C. Prendergast et al.
CANCER RESEARCH (2017)
In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions
Qiang Zhang et al.
DRUG METABOLISM AND DISPOSITION (2017)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2017)
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Andrew J. Gunderson et al.
CANCER DISCOVERY (2016)
Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia
Kyoung Eun Lee et al.
CANCER DISCOVERY (2016)
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Henrique Lemos et al.
CANCER RESEARCH (2016)
Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
Arta M. Monjazeb et al.
CLINICAL CANCER RESEARCH (2016)
IDO1 is an Integral Mediator of Inflammatory Neovascularization
Arpita Mondal et al.
EBIOMEDICINE (2016)
A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
Nicholas C. D'Amato et al.
CANCER RESEARCH (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
George C. Prendergast et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
IDO2 in immunomodulation and autoimmune disease
George C. Prendergast et al.
FRONTIERS IN IMMUNOLOGY (2014)
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Small molecule modulators of eukaryotic initiation factor 2α kinases, the key regulators of protein synthesis
Manali Joshi et al.
BIOCHIMIE (2013)
Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive T-cells
Theodoros Eleftheriadis et al.
HUMAN IMMUNOLOGY (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target
Stephen Safe et al.
TOXICOLOGICAL SCIENCES (2013)
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2013)
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Courtney Smith et al.
CANCER DISCOVERY (2012)
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan
Richard Metz et al.
ONCOIMMUNOLOGY (2012)
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Yan-Jie Zhang et al.
DRUG DISCOVERY TODAY (2011)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
CANCER Why tumours eat tryptophan
George C. Prendergast
NATURE (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate
Alexander J. Muller et al.
CANCER RESEARCH (2010)
Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation
Alexander J. Muller et al.
IMMUNOTHERAPY (2010)
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
Stefan Loeb et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
Agnieszka K. Witkiewicz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Infectious tolerance via the consumption of essential amino acids and mTOR signaling
Stephen P. Cobbold et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection
Agnes Witkiewicz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
Alexander J. Muller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase
T. Banerjee et al.
ONCOGENE (2008)
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
Richard Metz et al.
CANCER RESEARCH (2007)
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice
Helen J. Ball et al.
GENE (2007)
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Alexander J. Muller et al.
NATURE REVIEWS CANCER (2006)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Share Paper
